Recent Events & Catalysts
Spyre Therapeutics, Inc. (SYRE) — real, dated facts. Not a claim about what caused any single day's price move.
Committee Signals
Proprietary signals generated by the Innellis AI committee — score changes, rating shifts, and analyst disagreements.
No committee signals recorded yet.
News
Target To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Tuesday
Benzinga · today
BTIG Maintains Buy on Spyre Therapeutics, Raises Price Target to $132
Benzinga · today
Spyre Therapeutics Launches New Combination Program SPY772, Comprising Long-Acting Anti-TL1A Antibody SPY072 And Novel Long-Acting Anti-IL-17A/F Antibody In Preclinical Development SPY007
Benzinga · 1d ago
Wells Fargo Maintains Overweight on Spyre Therapeutics, Raises Price Target to $115
Benzinga · 6d ago
Guggenheim Maintains Buy on Spyre Therapeutics, Raises Price Target to $130
Benzinga · 6d ago
Wedbush Maintains Outperform on Spyre Therapeutics, Raises Price Target to $130
Benzinga · 6d ago
Spyre Therapeutics Q2 EPS $(0.36) Beats $(0.73) Estimate
Benzinga · 7d ago
Wolfe Research Downgrades Spyre Therapeutics to Peer Perform
Benzinga · 14d ago
SEC Filings (90 days)
Results of operations (earnings release), Financial statements and exhibits
Filed 2026-08-04 · 7d ago · Material
Regulation FD disclosure, Other events, Financial statements and exhibits
Filed 2026-06-15 · 57d ago
Other events, Financial statements and exhibits
Filed 2026-06-01 · 71d ago
Departure/appointment of directors or officers, Submission of matters to a vote of security holders, Financial statements and exhibits
Filed 2026-05-29 · 74d ago
Earnings
No recent earnings data available.
Latest Analyst Action
No recent analyst actions available.